Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140

Speckled 140 KDa (SP140) is a nuclear body protein, mainly expressed in immune cells, which contains multiple domains suggestive of an epigenetic reader function; namely a bromodomain, a PHD domain and a SAND domain. Single nucleotide polymorphisms and epigenetic modifications in the SP140 locus have been linked to autoimmune and inflammatory diseases including Crohn’s disease (CD). However, little is known about the cellular function of SP140; this is due in part to the fact that, unlike for other many other epigenetic proteins, no small molecule inhibitors have been available to investigate the biological role of SP140. We report the discovery of the first small molecule SP140 inhibitor (GSK761) and utilize this to elucidate SP140 function in innate immune cells. We show that SP140 is highly expressed in CD68+ CD mucosal macrophages and in in vitro- generated inflammatory macrophages. SP140 inhibition through GSK761 reduced monocyte differentiation into inflammatory macrophages and lipopolysaccharide (LPS)-induced inflammatory activation, whilst inducing the generation of CD206+ regulatory macrophages that mark anti-TNF remission induction in CD patients. ChIP-seq analyses revealed that SP140 preferentially occupies transcriptional start sites (TSS) in inflammatory macrophages, with enrichment at gene loci encoding pro-inflammatory cytokines/chemokines and inflammatory pathways. GSK761 specifically reduced SP140 binding and thereby expression of SP140-dependent downstream inflammatory genes. Notably, in CD14+ macrophages isolated from CD intestinal-mucosa, GSK761 inhibited the spontaneous expression of cytokines, including TNF . Together, this study identifies SP140 as a druggable epigenetic reader and therapeutic target for CD. ### Competing Interest Statement PDC, AYFLY, AS, SH, RPB, KG, GY, HPK, AC, AP, LAS, DJM, LL, RJW, CEB, LAH, GB, UK, NH, JRP, RKP, NRH and DFT were employed by GSK at the time of conducting this study. MG, JK, ILH, DAZ, OW, TBMH, JVL, PH, MPJW and WJDJ were employed by Amsterdam University Medical Centers at the time of conducting this study. GSK has a patent EP2643462B1 related to the therapeutic use of SP140 inhibitors.